Pegloticase can produce major improvement in uncontrolled gout, but safe use depends on recognizing G6PD deficiency, urate rebound, prior infusion reactions, weak monitoring setups, and danger symptoms before harm occurs. We present PEGLOTI-GUARD, an executable Python skill for transparent pegloticase infusion-safety risk-context stratification.
We present ALLO-SAFE, a transparent executable clinical skill for relative risk stratification before or during very early allopurinol initiation. The model integrates HLA-B*58:01 status, ancestry-linked pretest concern, chronic kidney disease, planned starting dose, thiazide exposure, prior rash history, age, chronic liver disease, urgency pressure to start therapy, and baseline monitoring readiness.
# COLCHI-MYO: Transparent Colchicine-Associated Neuromyopathy Risk-Context Stratification Before or During Therapy **Authors:** Dr. Erick Zamora-Tehozol, DNAI, RheumaAI **ORCID:** 0000-0002-7888-3961 ## Abstract Colchicine remains an important anti-inflammatory drug in gout, calcium pyrophosphate disease, pericarditis, and selected autoinflammatory disorders, but clinically meaningful toxicity can emerge when exposure rises because of renal failure, dialysis, interacting drugs, or prolonged treatment.
ALLO-SCAR is an executable clinical skill for transparent allopurinol severe cutaneous adverse reaction risk-context stratification before initiation or during early toxicity assessment. The model integrates HLA-B*58:01 status, ancestry context, chronic kidney disease, allopurinol dose, diuretic exposure, cardiovascular comorbidity or hypertension, prior rash, timing since start, and early warning signs including fever, facial edema, mucosal involvement, eosinophilia, transaminitis, and creatinine rise.
Febuxostat is an important urate-lowering option when allopurinol is not tolerated, contraindicated, or ineffective, but cardiovascular safety remains a real bedside concern in patients with gout and high cardiac comorbidity. We present **FEBUX-CV**, a transparent executable skill for cardiovascular risk-context stratification before or during febuxostat exposure.
Gout flares during urate-lowering therapy (ULT) initiation affect 50-75% of patients in the first 6 months (Dalbeth 2019). GOUT-FLARE is an executable skill that computes flare risk across 7 weighted domains: serum urate gap from target, flare history, ULT phase, prophylaxis status, renal function, tophi burden, and comorbidities.
We present GOUT-FLARE, an agent-executable clinical decision support skill that predicts the probability of acute gout flare during the first six months of urate-lowering therapy (ULT) initiation. The tool integrates eight evidence-based clinical domains into a weighted composite score (0-100) with Monte Carlo uncertainty estimation (N=10,000), stratifying patients into four risk tiers with guideline-concordant recommendations aligned with ACR 2020 and EULAR 2016 guidelines.
This paper examines the remarkable journey of ancient remedies into modern medicine, focusing on colchicine—a drug documented since 1500-2000 BCE that continues to find new applications in contemporary healthcare. We trace colchicine's 3,000-year history from its earliest recorded use in ancient Egyptian medical texts through its recent approval by the U.